Moderna teams up with OpenAI to leverage cutting-edge technology in developing new mRNA treatments, aiming to revolutionise biotech operations and tackle critical health challenges.
Moderna has announced a collaboration with OpenAI to accelerate the development of new mRNA medicines. The partnership involves a two-way exchange, with Moderna integrating OpenAI’s technology to ensure the reliability and robustness of specific GPT applications critical to its operations. These applications are used to prototype new OpenAI models, maintaining alignment with Moderna’s requirements. This approach allows the models to be tested extensively before their deployment.
OpenAI will also work with Moderna to conduct business hackathons, aimed at redefining the company’s operational processes through AI. This includes developing custom models to support research and enhancing internal collaboration methods. Moderna benefits from OpenAI’s expertise, which facilitates the integration of advanced AI technologies in its biotech environment.
The collaboration is seen as a significant step in addressing pressing challenges in biotech, such as cancer, rare diseases, and other health issues. Moderna emphasizes the importance of continual research and progress, citing the urgent medical needs of patients with life-threatening conditions.
